GSK3β genetic variability in patients with Multiple Sclerosis.
about
Inhibition of Drp1 hyper-activation is protective in animal models of experimental multiple sclerosis.Cyclin-dependent kinase 5 mediates adult OPC maturation and myelin repair through modulation of Akt and GsK-3β signaling.Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter.Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls.Wnt and lithium: a common destiny in the therapy of nervous system pathologies?Wnt signaling in remyelination in multiple sclerosis: friend or foe?
P2860
GSK3β genetic variability in patients with Multiple Sclerosis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
GSK3β genetic variability in patients with Multiple Sclerosis.
@ast
GSK3β genetic variability in patients with Multiple Sclerosis.
@en
type
label
GSK3β genetic variability in patients with Multiple Sclerosis.
@ast
GSK3β genetic variability in patients with Multiple Sclerosis.
@en
prefLabel
GSK3β genetic variability in patients with Multiple Sclerosis.
@ast
GSK3β genetic variability in patients with Multiple Sclerosis.
@en
P2093
P50
P1433
P1476
GSK3β genetic variability in patients with Multiple Sclerosis.
@en
P2093
Claudia Cantoni
David Comings
Diego Scalabrini
Elisa Ridolfi
Francesco Monaco
James Macmurray
Ma-Hin Fardipoor
Maria Serpente
Milena De Riz
P356
10.1016/J.NEULET.2011.04.024
P407
P50
P577
2011-04-17T00:00:00Z